Eutilex saw the highest growth of 0.99% in patent filings in April and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Eutilex’s patent filings and grants. Buy the databook here.
Eutilex has been focused on protecting inventions in Japan(JP) with two publications in Q2 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 33% filings and 33% grants. The Japan(JP), South Korea(KR), World Intellectual Property Organization(WIPO), and European Patent Office(EPO) patent Office are among the top ten patent offices where Eutilex is filings its patents. Among the top granted patent authorities, Eutilex has 33% of its grants in Japan(JP), 33% in South Korea(KR) and 33% in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Eutilex
Patents related to rare diseases lead Eutilex's portfolio
Eutilex has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Leukemia related patents lead Eutilex portfolio followed by lymphoma, and diffuse large b-cell lymphoma
Eutilex has highest number of patents in leukemia followed by lymphoma, diffuse large b-cell lymphoma, adenocarcinoma, and squamous cell carcinoma.
For comprehensive analysis of Eutilex's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.